Journal
SEMINARS IN IMMUNOLOGY
Volume 51, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2021.101475
Keywords
HIV; Broadly neutralizing antibodies; Clinical evaluation; Therapy and prevention
Categories
Funding
- Ragon Institute of MGH, MIT and Harvard
Ask authors/readers for more resources
The discovery of potent and broadly neutralizing antibodies against HIV-1 has led to significant advancements in developing tools for the prevention and treatment of HIV-1 infections, showing promise for clinical use.
Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional tools to prevent and treat HIV-1 are therefore necessary. The identification of potent and broadly neutralizing antibodies (bNAbs) against HIV-1 has revolutionized the field and may prove clinically useful. Significant advances have been made in identifying broader and more potent antibodies, characterizing antibodies in preclinical animal models, engineering antibodies to extend half-life and expand breadth and functionality, and evaluating the efficacy of single bNAbs and bNAb combinations in people with and without HIV-1. Here, we review recent progress in developing bNAbs for the prevention and treatment of HIV-1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available